MedTrace Logo

Pharmacokinetics of Caspofungin After One Dose in Patients With Liver Failure

NCT01968395 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2019-02-15

No results posted yet for this study

Summary

The objective of this study is to conduct a population pharmacokinetic analysis of caspofungin in a population of patients with moderate and severe acute alcoholic hepatitis or liver disease with Child-Pugh score B and C in order to better characterize pharmacokinetic parameters in case of moderate and severe liver dysfunction.

Conditions

Interventions

DRUG

Caspofungin 70 mg

Intravenous use

Sponsors & Collaborators

  • Erasme University Hospital

    lead OTHER

Principal Investigators

  • Frédérique JACOBS, MD,PhD · Erasme University Hospital

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-30
Primary Completion
2014-08-31
Completion
2014-10-21

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01968395 on ClinicalTrials.gov